glp 1 approved for cardiovascular disease GLP-1 Agonists in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies A new Science Perspective highlights

AOD9604 is studied for stimulating fat breakdown specifically, without the bone growth, muscle growth, or insulin resistance effects typically associated with full-length growth hormone administration

Translocation of perilipin and hormone-sensitive lipase in response to lipolytic hormones

These findings indicated that EGCG-Zn retained the antioxidant and DNA-protective properties of EGCG in normal intestinal epithelial cells while not compromising the cytotoxic efficacy of radiotherapy against malignant cells in the tested cancer cell line

Additional gut hormones, including peptide YY (PYY) , glucagon-like peptide-1 (GLP-1) , and cholecystokinin (CCK) , are released in response to food intake and contribute to the sensation of fullness by slowing digestion and communicating with appetite centres in the brain

J Pediatr Surg 2009

[00:28:40] Emily Field: Because if we just want this whole episode talking about why muscle matters, why training matters, and why preserving strength matters, then we also have to acknowledge this